AU2001231016A1 - Peptides with antibacterial activity - Google Patents

Peptides with antibacterial activity

Info

Publication number
AU2001231016A1
AU2001231016A1 AU2001231016A AU3101601A AU2001231016A1 AU 2001231016 A1 AU2001231016 A1 AU 2001231016A1 AU 2001231016 A AU2001231016 A AU 2001231016A AU 3101601 A AU3101601 A AU 3101601A AU 2001231016 A1 AU2001231016 A1 AU 2001231016A1
Authority
AU
Australia
Prior art keywords
inhibiting
peptides
antibacterial activity
endotoxemia
tnf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001231016A
Inventor
Kevin H. Mayo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota filed Critical University of Minnesota
Publication of AU2001231016A1 publication Critical patent/AU2001231016A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Polypeptides and methods of use including treating bacterial infection and/or endotoxemia, decreasing the amount of TNF-alpha, inhibiting endothelial cell proliferation, inhibiting angiogenic-factor mediated inter-cellular adhesion molecule expression down-regulation, and inhibiting angiogenesis.
AU2001231016A 2000-01-20 2001-01-19 Peptides with antibacterial activity Abandoned AU2001231016A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17725500P 2000-01-20 2000-01-20
US60/177,255 2000-01-20
US21029700P 2000-06-08 2000-06-08
US60/210,297 2000-06-08
PCT/US2001/001916 WO2001053335A2 (en) 2000-01-20 2001-01-19 Peptides with antibacterial activity

Publications (1)

Publication Number Publication Date
AU2001231016A1 true AU2001231016A1 (en) 2001-07-31

Family

ID=26873090

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001231016A Abandoned AU2001231016A1 (en) 2000-01-20 2001-01-19 Peptides with antibacterial activity

Country Status (8)

Country Link
US (1) US7144982B2 (en)
EP (1) EP1252181B1 (en)
AT (1) ATE316097T1 (en)
AU (1) AU2001231016A1 (en)
CA (1) CA2397835A1 (en)
DE (1) DE60116733T2 (en)
ES (1) ES2252187T3 (en)
WO (1) WO2001053335A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511892A (en) * 1996-05-24 2000-09-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Synthesis of soluble beta-sheet forming peptide
WO2001053335A2 (en) 2000-01-20 2001-07-26 Regents Of The University Of Minnesota Peptides with antibacterial activity
WO2003070751A2 (en) * 2002-02-20 2003-08-28 Regents Of The University Of Minnesota Partial peptide mimetics and methods
EP1380290A1 (en) 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
WO2004045583A1 (en) * 2002-11-15 2004-06-03 Nipro Corporation Liposome
NZ540895A (en) * 2003-01-09 2007-03-30 Genentech Inc Purification of polypeptides with ethacridine lactate
WO2005009457A1 (en) * 2003-05-15 2005-02-03 Sangstat Medical Corporation Rdp58 compositions and methods for inhibiting vascularization of cell populations
WO2005042699A2 (en) * 2003-10-17 2005-05-12 Regents Of The University Of Minnesota Modified polypeptides with therapeutic activity and methods of use
ATE421971T1 (en) * 2004-03-17 2009-02-15 Aplagen Gmbh ISOSTERIC TRANSFORMATION
CA2867023A1 (en) * 2004-10-04 2006-04-20 Kevin H. Mayo Calixarene-based peptide conformation mimetics, methods of use, and methods of making
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1910844B1 (en) 2005-07-13 2012-04-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
US10611799B2 (en) * 2017-03-03 2020-04-07 National Tsing Hua University Anti-endotoxin polypeptide
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5595887A (en) 1990-07-16 1997-01-21 Bionebraska, Inc. Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment
US5348942A (en) 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5786324A (en) 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5830860A (en) 1994-03-24 1998-11-03 Regents Of The University Of Minnesota Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
US5955577A (en) 1996-06-27 1999-09-21 Regents Of The University Of Minnesota Method for synthesizing a water-soluble β-sheet forming peptide
CA2273186A1 (en) 1997-10-07 1999-04-15 New England Medical Center Hospitals, Inc. Structure-based rational design of compounds to inhibit papillomavirus infection
JP4037525B2 (en) 1998-03-25 2008-01-23 生化学工業株式会社 New antibacterial peptide
WO2001053335A2 (en) 2000-01-20 2001-07-26 Regents Of The University Of Minnesota Peptides with antibacterial activity

Also Published As

Publication number Publication date
CA2397835A1 (en) 2001-07-26
EP1252181B1 (en) 2006-01-18
WO2001053335A2 (en) 2001-07-26
EP1252181A2 (en) 2002-10-30
US7144982B2 (en) 2006-12-05
ES2252187T3 (en) 2006-05-16
WO2001053335A9 (en) 2002-10-31
US20020146406A1 (en) 2002-10-10
DE60116733D1 (en) 2006-04-06
DE60116733T2 (en) 2006-11-02
WO2001053335A3 (en) 2001-12-13
ATE316097T1 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
AU2001231016A1 (en) Peptides with antibacterial activity
AU4608500A (en) An article of clothing having antibacterial, antifungal, and antiyeast properties
AU6339599A (en) Quinoline derivatives and their use as antibacterial agents
DE69635419D1 (en) ALKALOPHILES AND THERMOPHILIC MICRO-ORGANISMS AND ENZYMES OBTAINED THEREOF
AU6825300A (en) Compounds
AU1076101A (en) Enzymes useful for changing the properties of polyester
AU4107300A (en) Polyurethane solutions containing alkoxysilane structural units
EP1560821B8 (en) Antibacterial agents
ZA200108912B (en) Attenuated microorganisms for the treatment of infection.
IL156942A0 (en) Compounds, pharmaceutical compositions and methods for treatment of bacteremia and/or septicemia
WO2002000687A3 (en) Antimicrobial peptides and methods of use thereof
AU4640997A (en) Use of an H+, K+-ATPase inhibitor in the treatment of nasal polyps
AU2003294565A1 (en) Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
WO2004047771A3 (en) Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof
WO2003087353A3 (en) Purified polypeptides involved in membrane biogenesis
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
AU7980300A (en) Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics
WO2001034182A3 (en) Composition for treating respiratory tract infections containing menthol, eucalyptol and an alpha-amylase
WO2004072093A3 (en) Antimicrobial agents from streptococcus mitis and streptococcus oralis
AU1201801A (en) Treatment of dermal tumors, warts, and viral infections using heat-killed p. acnes
AU2001230243A1 (en) Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic diseases or stroke
AU1923501A (en) Pyridinones to treat and prevent bacterial infections
AU3456900A (en) Silver-containing complex protein and antibacterial/antifungal agents and antibacterial/antifungal papers with the use of the same
AU2001280464A1 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof